The Taiwan Interstitial Lung Disease (ILD) Multi-center Investigation and Registry aims to evaluate the long-term outcomes of patients with fibrotic interstitial lung disease. This prospective observational registry will collect comprehensive clinical data from multiple centers, including epidemiological information, comorbidities, questionnaire results, routine blood tests, biochemical tests, pulmonary function tests, echocardiograms, and cardiopulmonary exercise tests (CPET), all following a standardized protocol. Key components of the registry include annual HRCT scans, annual CPETs, biobank blood samples, and biannual echocardiograms and pulmonary function tests. The main questions the registry aims to answer are: 1. Differences in all-cause mortality among ILD patients of different etiologies. 2. Differences in the annual risk of acute exacerbation among ILD patients of different etiologies. 3. Effectiveness of current anti-fibrotic drugs in treating IPF and ILD of different etiologies. 4. Predictive ability of HRCT imaging features for mortality risk in ILD patients. 5. Impact of comorbidities on the mortality risk of ILD patients. 6. Predictive ability of biomarkers for disease progression and mortality.
The goal of this prospective observational registry is to evaluate the long-term outcomes of patients diagnosed with fibrotic interstitial lung disease in Taiwan. The investigators will conduct a prospective registry and collect clinical data of fibrotic lung disease patients from multiple centers in Taiwan. The data collected will include basic epidemiological information, comorbidities, questionnaire results, routine blood tests, biochemical tests, pulmonary function tests, echocardiograms, and cardiopulmonary exercise tests (CPET). Each hospital will follow the same protocol for data collection, establishing a real-world Taiwan Fibrotic Lung Disease Registry Database. The details of this registry plan include: 1. Annual high-resolution computed tomography (HRCT) scans 2. Annual cardiopulmonary exercise tests (CPET) 3. Peripheral blood sampling for inclusion in a biobank 4. Additionally, echocardiograms and pulmonary function tests will be conducted every six months. The main questions it aims to answer are: 1. Is there a difference in all-cause mortality among ILD patients of different etiologies? 2. Is there a difference in the annual risk of acute exacerbation among ILD patients of different etiologies? 3. Evaluate the real-world data on the effectiveness of current anti-fibrotic drugs in treating idiopathic pulmonary fibrosis (IPF) and ILD of different etiologies. 4. Investigate the predictive ability of high-resolution computed tomography (HRCT) imaging features for mortality risk in ILD patients. 5. Explore the impact of comorbidities on the mortality risk of ILD patients. 6. Assess the predictive ability of biomarkers for disease progression and mortality.
Study Type
OBSERVATIONAL
Enrollment
10,000
Taichung Veterans General Hospital
Taichung, Taiwan
RECRUITINGAll-cause mortality
All-cause mortality of the enrolled patients from enrollment to the death event
Time frame: 10 years
Annual rate of acute exacerbation
The event of visiting the emergency room or being hospitalized will be recorded
Time frame: through study completion, an average of 1 year
Annual rate of progressive pulmonary fibrosis
By the definition according to ATS 2022 guideline, including symptoms worsening, Lung function declined (FVC decreased more than 5 % or DLCO decreased more than 10% within one year) and the image pattern showed progression on HRCT scan
Time frame: From date of enrolled until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.